NICE Recommends GSK's Omjjara as treatment option for myelofibrosis patients with anaemia
The National Institute for Health and Care Excellence (NICE) has issued guidance recommending GSK's Omjjara (momelotinib) as a treatment option for disease-related splenomegaly.
